Due to the number of inquiries, I am not able to take intro calls regarding board roles. If you are interested in pitching board/advisor opportunities to me, please send details of the company or venture firm.
Vendors/CROs etc, please contact info@seaporttx.com to get connected to the right leaders within Seaport.
For jobs, please contact careers@seaporttx.com
Due to the number of inquiries, I am not able to take intro calls regarding board roles. If you are interested in pitching board/advisor opportunities to me, please send details of the company or venture firm.
Vendors/CROs etc, please contact info@seaporttx.com to get connected to the right leaders within Seaport.
For jobs, please contact careers@seaporttx.com
Yesterday, our Co-founder and Chief Executive Officer,Daphne Zohar, presented at theJ.P. MorganHealthcare Conference, sharing the recent progress Seaport has made and our path forward as we tackle some of the biggest medical problems our population is facing today. With our clinically validated Glyph™ platform that has yielded a robust pipeline, we’re pleased with the key development milestones, including across our two clinical-stage programs: GlyphAllo™ (Glyph Allopregnanolone), which we’re advancing in a Phase 2b trial for the treatment of major depressive disorder, and GlyphAgo™ (Glyph Agomelatine), which we’re advancing in a Phase 1 proof-of-concept trial for the treatment of generalized anxiety disorder. We have a seasoned leadership team that has a proven track record of bringing new medicines to patients, and we look forward to continued progress toward developing potentially first-in-class and best-in-class drug candidates forhashtag#depression,hashtag#anxiety, and otherhashtag#neuropsychiatricdisorders with significant unmet need. Daphne was also joined on stage bySteven Paul, M.D., Co-founder and Chair, andMichael C. Chen, Ph.D., Co-founder and Chief Scientific Officer for the Q&A portion of the presentation, and other members of our Seaport team at the conference.hashtag#JPM26hashtag#JPMHC26
We’re proud to partner with this group of new and existing investors who share our commitment of delivering better medicines for those suffering fromhashtag#depression,hashtag#anxietyand otherhashtag#neuropsychiatricdisorders. The proceeds will be used to advance our clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of our Glyph™ technology platform.https://bwnews.pr/4eQ6FHm
On today’shashtag#BiotechHangout,Eric Schmidt,Mike Yee,Yaron Werber&Matthew Glinewill cover market sentiment: overall volatility of sector given macro conditions & “risk-off” environment, company news: $2B+ settlement between $ROIV / $MRNA plus implications for $PFE & biotech IP, $QURE “he said/she said” & latest FDA controversy - pressures mounting for Makary & Prasad, $HROW’s financial guidance, a discussion on sandbagging & stock price dynamics around “late pre-revenue” stocks vs commercial stocks, obesity news: impact of obesity drugs on consumer sector, broader implications of GLP-1 brigade, Miami “is hot” w/ biotech conferences next week: Leerink, UBS, Barclays, Jefferies & much more. Tune in at 12pm ET:https://lnkd.in/eB8a45n2
Founder, CEO & Board Member at PureTech Health, Boston, MA · http://www.puretechhealth.comFounder, CEO & Board Member at PureTech Health, Boston, MA · http://www.puretechhealth.com
Mark was a key investor in my former company and is thoughtful, experienced and pragmatic. Was a pleasure to work with him!Mark was a key investor in my former company and is thoughtful, experienced and pragmatic. Was a pleasure to work with him!
Tune in at 12pm ET: https://lnkd.in/eB8a45n2